In 2026 we will witness a host of medical advances that have been in development for many years, in some cases decades, as painstaking R&D work culminates in major breakthroughs. Everything from GLP-1 drugs for weight loss to bispecific antibodies for cancer, from radiopharmaceuticals to cell and gene therapies. 

This new generation of innovative treatments is now making its way to market, bringing hope to patients.

The landscape of these spectacular advances is forensically monitored by Clarivate, the most promising of which are profiled in their annual edition of ‘Drugs to Watch’.

Over the course of a decade, Texture has created the campaign concept and creative expression of each edition, creating a higher and higher benchmark with each passing year.

This year's edition took the profound nature of the breakthroughs, and positioned them as ‘worth their wait’. The gold tinged, three dimensional images showcase a biology of impact these drugs will deliver. The visuals and their associated copy offer a stunning celebration of what’s to come and the value they represent.